Log in

NASDAQ:CYCCPCyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs Stock Price, Forecast & News

$5.50
0.00 (0.00 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.50
Now: $5.50
$5.50
50-Day Range
$5.48
MA: $6.16
$7.75
52-Week Range
$3.87
Now: $5.50
$8.07
VolumeN/A
Average Volume713 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.12%
BetaN/A
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCCP
CUSIPN/A
Phone+1-908-5177330

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14
Next Earnings DateN/A
OptionableNot Optionable

Receive CYCCP News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCCP and its competitors with MarketBeat's FREE daily newsletter.

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (NASDAQ:CYCCP) Frequently Asked Questions

How has Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock been impacted by COVID-19 (Coronavirus)?

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock was trading at $6.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYCCP stock has decreased by 10.6% and is now trading at $5.50. View which stocks have been most impacted by Coronavirus.

How often does Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs pay dividends? What is the dividend yield for Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs?

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs announced a quarterly dividend on Wednesday, July 1st. Stockholders of record on Friday, July 17th will be paid a dividend of $0.15 per share on Saturday, August 1st. This represents a $0.60 dividend on an annualized basis and a dividend yield of 10.91%. The ex-dividend date of this dividend is Thursday, July 16th. View Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' dividend history.

Has Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs been receiving favorable news coverage?

Media headlines about CYCCP stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs.

Who are some of Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' key competitors?

Who are Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' key executives?

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' management team includes the following people:
  • Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)
  • Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)
  • Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)
  • Ms. Gill Christie, Director of HR (Age 62)
  • Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75)

What is Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock symbol?

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs trades on the NASDAQ under the ticker symbol "CYCCP."

How do I buy shares of Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs?

Shares of CYCCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock price today?

One share of CYCCP stock can currently be purchased for approximately $5.50.

What is Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' official website?

The official website for Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs is www.cyclacel.com.

How can I contact Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs?

Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' mailing address is 200 Connell Dr Ste 1500, BERKELEY HEIGHTS, NJ 07922-2811, United States. The company can be reached via phone at +1-908-5177330.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.